{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-25-000156","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.578049+00:00","generated_at":"2026-05-24T03:30:28.108290+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vertex halts VX-264 type 1 diabetes program; expects ~$400M impairment charge","bullets":["Phase 1/2 trial of VX-264 for type 1 diabetes fails; program will not advance further.","Vertex expects non-cash impairment charge of ~$400M from VX-264 intangible assets in Q1 and FY 2025.","Preliminary analysis; Vertex will disclose final impairment results in Q1 2025 Form 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-25-000156","json":"https://secwatch.observer/filing/0000875320-25-000156.json","markdown":"https://secwatch.observer/filing/0000875320-25-000156.md","text":"https://secwatch.observer/filing/0000875320-25-000156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000156/0000875320-25-000156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000156/vrtx-20250328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:30:28.108290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}